scopolamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2424 51-34-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • scopolamine
  • scopolamine hydrobromide
  • hyoscine
  • levo-duboisine
  • scopoderm
  • scopolamine hydrochloride
  • scopolamine HCl
An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic.
  • Molecular weight: 303.36
  • Formula: C17H21NO4
  • CLOGP: 0.09
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 62.30
  • ALOGS: -1.66
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.90 mg O
0.90 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 666.67 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 27 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1979 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anticholinergic syndrome 95.06 14.58 26 7019 1769 50596310
Mydriasis 90.18 14.58 39 7006 10588 50587491
Akathisia 69.16 14.58 30 7015 8199 50589880
Vomiting 33.04 14.58 139 6906 460619 50137460
Neutrophil count increased 30.63 14.58 21 7024 14174 50583905
Product adhesion issue 30.46 14.58 14 7031 4378 50593701
Infectious mononucleosis 27.88 14.58 10 7035 1656 50596423
Drug ineffective 24.83 14.58 48 6997 819285 49778794
Application site rash 24.50 14.58 10 7035 2347 50595732
Differential white blood cell count abnormal 23.03 14.58 7 7038 692 50597387
Tachyarrhythmia 22.11 14.58 11 7034 4094 50593985
Vision blurred 21.55 14.58 39 7006 78608 50519471
Suicidal ideation 21.29 14.58 32 7013 55353 50542726
Porphyria acute 20.85 14.58 6 7039 491 50597588
Nausea 20.22 14.58 167 6878 705231 49892848
Hallucination 19.44 14.58 28 7017 46629 50551450
Application site reaction 19.04 14.58 6 7039 668 50597411
Blood lactic acid increased 18.93 14.58 11 7034 5574 50592505
Colitis 18.87 14.58 25 7020 38504 50559575
Application site erythema 18.26 14.58 10 7035 4528 50593551
Abdominal pain 18.21 14.58 73 6972 236155 50361924
Hyperkinesia 18.02 14.58 7 7038 1445 50596634
Blood alkaline phosphatase increased 17.84 14.58 24 7021 37502 50560577
Intra-abdominal haematoma 17.54 14.58 7 7038 1550 50596529
Drug monitoring procedure incorrectly performed 17.40 14.58 4 7041 133 50597946
Cardiac output decreased 17.34 14.58 6 7039 894 50597185
Antipsychotic drug level above therapeutic 16.97 14.58 6 7039 953 50597126
Disorientation 15.82 14.58 22 7023 35462 50562617
Small intestinal obstruction 15.79 14.58 15 7030 16053 50582026
Device occlusion 15.63 14.58 10 7035 6013 50592066
Urine output decreased 14.81 14.58 12 7033 10409 50587670
Salivary hypersecretion 14.81 14.58 10 7035 6581 50591498
Joint swelling 14.59 14.58 8 7037 245278 50352801

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prescription drug used without a prescription 86.44 17.84 24 5507 1280 29567716
Neutrophil count increased 83.58 17.84 45 5486 14697 29554299
Failure to suspend medication 59.62 17.84 14 5517 378 29568618
White blood cell count increased 49.55 17.84 47 5484 37469 29531527
Neuroleptic malignant syndrome 41.96 17.84 30 5501 16118 29552878
Wrong patient received product 38.84 17.84 15 5516 2267 29566729
Accidental death 36.33 17.84 14 5517 2104 29566892
Salivary hypersecretion 34.81 17.84 20 5511 7389 29561607
Platelet count decreased 32.77 17.84 65 5466 104607 29464389
Platelet count increased 32.35 17.84 20 5511 8443 29560553
Ideas of reference 32.34 17.84 6 5525 48 29568948
Antipsychotic drug level decreased 31.37 17.84 10 5521 859 29568137
Lymphocyte count decreased 31.03 17.84 27 5504 19244 29549752
Toxicity to various agents 29.51 17.84 85 5446 173576 29395420
Red blood cell elliptocytes present 28.95 17.84 6 5525 89 29568907
Hallucination 27.97 17.84 38 5493 44674 29524322
Differential white blood cell count abnormal 27.66 17.84 10 5521 1259 29567737
White blood cell count decreased 27.57 17.84 53 5478 83309 29485687
Antipsychotic drug level increased 27.47 17.84 13 5518 3230 29565766
Neutrophil count decreased 27.21 17.84 37 5494 43530 29525466
Confusional state 27.15 17.84 68 5463 127809 29441187
Pneumonia aspiration 25.72 17.84 33 5498 36704 29532292
Serotonin syndrome 25.14 17.84 23 5508 17489 29551507
Incision site pain 24.35 17.84 10 5521 1773 29567223
Portal tract inflammation 24.01 17.84 5 5526 76 29568920
Schizophrenia 23.79 17.84 15 5516 6550 29562446
Pneumoconiosis 23.60 17.84 6 5525 227 29568769
Product adhesion issue 22.67 17.84 9 5522 1462 29567534
Mental impairment 21.51 17.84 16 5515 9125 29559871
Mean cell volume decreased 20.92 17.84 8 5523 1177 29567819
Seizure 20.25 17.84 50 5481 93073 29475923
Mydriasis 19.81 17.84 13 5518 6072 29562924
Drug ineffective 19.13 17.84 24 5507 363146 29205850
Convulsive threshold lowered 19.03 17.84 6 5525 497 29568499
Body temperature increased 18.84 17.84 18 5513 14447 29554549
Agitation 18.66 17.84 34 5497 51270 29517726
Lung cancer metastatic 18.35 17.84 9 5522 2418 29566578
Intentional product misuse 18.04 17.84 27 5504 34634 29534362
Antipsychotic drug level above therapeutic 17.89 17.84 7 5524 1094 29567902

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutrophil count increased 117.93 15.18 65 10607 25109 64462951
Anticholinergic syndrome 84.53 15.18 27 10645 2642 64485418
Mydriasis 78.55 15.18 42 10630 15270 64472790
Akathisia 65.95 15.18 34 10638 11476 64476584
White blood cell count increased 56.70 15.18 62 10610 65952 64422108
Failure to suspend medication 55.56 15.18 13 10659 392 64487668
Neuroleptic malignant syndrome 54.96 15.18 40 10632 24956 64463104
Differential white blood cell count abnormal 51.97 15.18 17 10655 1793 64486267
Vomiting 44.15 15.18 194 10478 550923 63937137
Hallucination 40.66 15.18 55 10617 72733 64415327
Drug ineffective 40.37 15.18 48 10624 840199 63647861
Wrong patient received product 39.86 15.18 17 10655 3745 64484315
Lymphocyte count decreased 39.85 15.18 41 10631 40658 64447402
Salivary hypersecretion 37.61 15.18 24 10648 12089 64475971
Antipsychotic drug level above therapeutic 35.97 15.18 13 10659 1848 64486212
Antipsychotic drug level decreased 31.75 15.18 10 10662 934 64487126
Incision site pain 31.49 15.18 13 10659 2641 64485419
Antipsychotic drug level increased 28.98 15.18 15 10657 5100 64482960
Seizure 28.67 15.18 76 10596 166816 64321244
Platelet count increased 28.28 15.18 24 10648 18672 64469388
White blood cell count decreased 28.26 15.18 73 10599 157764 64330296
Confusional state 28.12 15.18 101 10571 261043 64227017
Constipation 27.56 15.18 92 10580 229245 64258815
Platelet count decreased 27.43 15.18 75 10597 167636 64320424
Accidental death 27.26 15.18 13 10659 3712 64484348
Red blood cell elliptocytes present 26.72 15.18 6 10666 150 64487910
Ideas of reference 26.53 15.18 6 10666 155 64487905
Agitation 24.94 15.18 49 10623 88318 64399742
Neutrophil count decreased 24.49 15.18 45 10627 77151 64410909
Pneumoconiosis 23.95 15.18 6 10666 242 64487818
Blood alkaline phosphatase increased 23.39 15.18 37 10635 56242 64431818
Mental impairment 22.74 15.18 20 10652 16323 64471737
Arthralgia 22.54 15.18 24 10648 442236 64045824
Portal tract inflammation 22.23 15.18 5 10667 126 64487934
Tachycardia 20.68 15.18 63 10609 149516 64338544
Pneumonia aspiration 20.65 15.18 36 10636 59235 64428825
Convulsive threshold lowered 20.11 15.18 7 10665 892 64487168
Antipsychotic drug level below therapeutic 19.49 15.18 7 10665 978 64487082
Serotonin syndrome 19.41 15.18 28 10644 39254 64448806
Mean cell volume decreased 19.06 15.18 10 10662 3496 64484564
Application site erythema 18.95 15.18 11 10661 4678 64483382
Dyskinesia 17.92 15.18 27 10645 39361 64448699
Porphyria acute 17.64 15.18 6 10666 714 64487346
Rheumatoid arthritis 17.60 15.18 3 10669 164291 64323769
Haemoglobin decreased 17.32 15.18 71 10601 194992 64293068
Electrocardiogram QT prolonged 16.59 15.18 39 10633 79409 64408651
Product administered to patient of inappropriate age 16.52 15.18 10 10662 4591 64483469
Somnolence 16.44 15.18 72 10600 203573 64284487
Joint swelling 15.72 15.18 8 10664 215374 64272686

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A04AD01 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Other antiemetics
ATC A04AD51 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Other antiemetics
ATC N05CM05 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Other hypnotics and sedatives
ATC S01FA02 SENSORY ORGANS
OPHTHALMOLOGICALS
MYDRIATICS AND CYCLOPLEGICS
Anticholinergics
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D009184 Mydriatics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:25212 metabolites
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:50513 mydriatics
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:53784 antispasmodics
CHEBI has role CHEBI:60807 anaesthestic adjuvant
CHEBI has role CHEBI:60809 adjuvants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Vasomotor rhinitis indication 8229003 DOID:4730
Irritable bowel syndrome indication 10743008 DOID:9778
Peptic ulcer indication 13200003 DOID:750
Motion sickness indication 37031009 DOID:2951
Dilated pupil indication 37125009
Cough indication 49727002
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Cycloplegia indication 68158006 DOID:10033
Nasal congestion indication 68235000
Iridocyclitis indication 77971008
Common cold indication 82272006 DOID:10459
Posterior synechiae indication 111512005
Uveitis indication 128473001 DOID:13141
Prevention of Posterior Synechiae indication
Perioperative Mydriasis indication
Prevention of Motion Sickness indication
Prevention of Post-Operative Nausea and Vomiting indication
General anesthesia off-label use 50697003
Excessive salivation off-label use 53827007
Rhinitis off-label use 70076002 DOID:4483
Seasonal allergic rhinitis off-label use 367498001
Brain damage contraindication 2470005
Ocular hypertension contraindication 4210003 DOID:9282
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hepatic encephalopathy contraindication 13920009 DOID:13413
Severe chronic ulcerative colitis contraindication 14311001
Disorder of autonomic nervous system contraindication 15241006
Disorder of lung contraindication 19829001 DOID:850
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Ventricular tachycardia contraindication 25569003
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypovolemic shock contraindication 39419009
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Acidosis contraindication 51387008
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Paralytic ileus contraindication 55525008 DOID:8442
Heart disease contraindication 56265001 DOID:114
Peptic reflux disease contraindication 57643001
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Poisoning by phenobarbital contraindication 64921004
Arterial thrombosis contraindication 65198009
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Chronic idiopathic constipation contraindication 82934008
Hiatal hernia contraindication 84089009 DOID:12642
Open-angle glaucoma contraindication 84494001 DOID:1067
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Magnetic resonance imaging contraindication 113091000
Hypoalbuminemia contraindication 119247004
Gastrointestinal obstruction contraindication 126765001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Myocardial dysfunction contraindication 233928007
Arterial aneurysm contraindication 233981004
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Severe chronic obstructive pulmonary disease contraindication 313299006
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic
pKa2 7.95 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9 WOMBAT-PK CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 8.86 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 9.40 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 7.75 CHEMBL
Muscarinic acetylcholine receptor M4 GPCR Ki 9.37 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Kd 8.52 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 9.28 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Kd 9.19 CHEMBL
Muscarinic receptor M1 GPCR Ki 9.39 CHEMBL
Muscarinic acetylcholine receptor DM1 GPCR Ki 9.15 CHEMBL
Muscarinic acetylcholine receptor GPCR Ki 10.10 CHEMBL

External reference:

IDSource
4018401 VUID
N0000146728 NUI
D00138 KEGG_DRUG
6533-68-2 SECONDARY_CAS_RN
4018399 VANDF
4018401 VANDF
4018412 VANDF
C0036442 UMLSCUI
CHEBI:16794 CHEBI
CHEMBL1187846 ChEMBL_ID
CHEMBL569713 ChEMBL_ID
DB00747 DRUGBANK_ID
CHEMBL2251240 ChEMBL_ID
CHEMBL1256744 ChEMBL_ID
D012601 MESH_DESCRIPTOR_UI
3000322 PUBCHEM_CID
330 IUPHAR_LIGAND_ID
55-16-3 SECONDARY_CAS_RN
DL48G20X8X UNII
9601 RXNORM
1472 MMSL
5444 MMSL
5445 MMSL
72365 MMSL
d00986 MMSL
001719 NDDF
003458 NDDF
387409009 SNOMEDCT_US
387477005 SNOMEDCT_US
72870001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Transderm Scop HUMAN PRESCRIPTION DRUG LABEL 1 0067-4346 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL NDA 29 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 0378-6470 PATCH 1 mg TRANSDERMAL ANDA 30 sections
Belladonna Alkaloids with Phenobartbital HUMAN PRESCRIPTION DRUG LABEL 4 0440-7183 TABLET 0.01 mg ORAL UNAPPROVED DRUG OTHER 14 sections
scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-2258 SYSTEM 1 mg TRANSDERMAL ANDA 27 sections
Transderm Scop HUMAN PRESCRIPTION DRUG LABEL 1 10019-553 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL NDA 29 sections
Phenohytro HUMAN PRESCRIPTION DRUG LABEL 4 17856-0123 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 18 sections
Phenohytro HUMAN PRESCRIPTION DRUG LABEL 4 17856-0125 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 18 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS HUMAN PRESCRIPTION DRUG LABEL 4 17856-0162 ELIXIR 0.01 mg ORAL unapproved drug other 16 sections
Donnatal HUMAN PRESCRIPTION DRUG LABEL 4 17856-0423 ELIXIR 0.01 mg ORAL unapproved drug other 12 sections
RE-PB HYOS ELIXIR HUMAN PRESCRIPTION DRUG LABEL 4 21695-594 ELIXIR 0.01 mg ORAL Unapproved drug other 11 sections
Belladonna Alkaloids with Phenobartbital HUMAN PRESCRIPTION DRUG LABEL 4 21695-890 TABLET 0.01 mg ORAL Unapproved drug other 15 sections
QUADRAPAX HUMAN PRESCRIPTION DRUG LABEL 4 21695-970 ELIXIR 0.01 mg ORAL Unapproved drug other 13 sections
Donnatal HUMAN PRESCRIPTION DRUG LABEL 4 42254-268 TABLET 0.01 mg ORAL Unapproved drug other 15 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS HUMAN PRESCRIPTION DRUG LABEL 4 42291-205 ELIXIR 0.01 mg ORAL unapproved drug other 17 sections
Donnatal HUMAN PRESCRIPTION DRUG LABEL 4 42291-245 TABLET 0.01 mg ORAL unapproved drug other 22 sections
Scopolamine Trandermal System HUMAN PRESCRIPTION DRUG LABEL 1 45802-580 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL ANDA 30 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 50090-5349 PATCH 1 mg TRANSDERMAL ANDA 30 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 50742-505 PATCH, EXTENDED RELEASE 1.50 mg TRANSDERMAL ANDA 30 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 50742-505 PATCH, EXTENDED RELEASE 1.50 mg TRANSDERMAL ANDA 30 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Human Prescription Drug Label 4 50742-665 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Human Prescription Drug Label 4 50742-666 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide Human Prescription Drug Label 4 50742-667 TABLET 0.01 mg ORAL UNAPPROVED DRUG OTHER 20 sections
Transderm Scop HUMAN PRESCRIPTION DRUG LABEL 1 54868-2803 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL NDA 24 sections
Donnatal Human Prescription Drug Label 4 59212-422 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 22 sections
Donnatal Human Prescription Drug Label 4 59212-423 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 22 sections
Donnatal Human Prescription Drug Label 4 59212-425 TABLET 0.01 mg ORAL UNAPPROVED DRUG OTHER 22 sections
Phenobarbital with Belladonna Alkaloids HUMAN PRESCRIPTION DRUG LABEL 4 63629-2050 TABLET 0.01 mg ORAL unapproved drug other 22 sections
Phenobarbital with Belladonna Alkaloids HUMAN PRESCRIPTION DRUG LABEL 4 63629-2050 TABLET 0.01 mg ORAL unapproved drug other 22 sections
Phenobarbital with Belladonna Alkaloids - Grape HUMAN PRESCRIPTION DRUG LABEL 4 63629-2051 ELIXIR 0.01 mg ORAL unapproved drug other 22 sections
Phenobarbital with Belladonna Alkaloids - Grape HUMAN PRESCRIPTION DRUG LABEL 4 63629-2051 ELIXIR 0.01 mg ORAL unapproved drug other 22 sections